N/A
Completed N=220
An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)
Source: ClinicalTrials.gov NCT01332981 ↗Enrolled (actual)
220
Serious AEs
—
Results posted
Feb 2016
Primary outcomePrimary: Median Overall Survival — 2.51 Years
Summary
This is an observational follow-up study on the efficacy of 1st-line treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer 7 years after initiation of treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Median Overall Survival |
2.51 | — |
| SECONDARY Median Time to Progression-Free Survival |
0.85 | — |
| SECONDARY Median Time to Progression |
0.85 | — |
| SECONDARY Median Treatment Duration and the Duration of Exposure to Trastuzumab |
1.19; 3.98 | — |
| SECONDARY Prognostic Factors for Overall Survival |
1.55; 1.49; 1.60; 1.55; 4.63; 4.70 | — |
| SECONDARY Prognostic Factors For Time to Progression |
1.34; NA; 1.44; 1.48; 2.81; 3.94 | — |
Eligibility Criteria
Inclusion Criteria
- Female patient, >/= 18 years of age
- Metastatic breast cancer
- 1st-line treatment with Herceptin initiated in 2002
- Included in pharmaco-epidemiologic HERMINE study
Exclusion Criteria
- Patient died before scheduled follow-up visit (March 2005)
Data sourced from ClinicalTrials.gov (NCT01332981). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.